⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for endometrial mixed cell adenocarcinoma

Every month we try and update this database with for endometrial mixed cell adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial CancerNCT02728258
Endometrial End...
Endometrial Mix...
Endometrial Ser...
Endometrial Und...
Metastatic Endo...
Recurrent Uteri...
Copanlisib
Laboratory Biom...
18 Years - NRG Oncology
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaNCT05112601
Endometrial Ade...
Endometrial Cle...
Endometrial Ded...
Endometrial End...
Endometrial Mix...
Endometrial Muc...
Endometrial Und...
Endometrioid Ad...
Recurrent Endom...
Biospecimen Col...
Computed Tomogr...
Ipilimumab
Magnetic Resona...
Nivolumab
18 Years - National Cancer Institute (NCI)
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial CancerNCT01935934
Endometrial Ade...
Endometrial Cle...
Endometrial Mix...
Endometrial Ser...
Metastatic Endo...
Recurrent Uteri...
Stage IV Uterin...
Stage IVA Uteri...
Stage IVB Uteri...
Uterine Corpus ...
Cabozantinib S-...
Laboratory Biom...
Pharmacological...
18 Years - National Cancer Institute (NCI)
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaNCT05112601
Endometrial Ade...
Endometrial Cle...
Endometrial Ded...
Endometrial End...
Endometrial Mix...
Endometrial Muc...
Endometrial Und...
Endometrioid Ad...
Recurrent Endom...
Biospecimen Col...
Computed Tomogr...
Ipilimumab
Magnetic Resona...
Nivolumab
18 Years - National Cancer Institute (NCI)
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial CancerNCT03914612
Endometrial Cle...
Endometrial Ded...
Endometrial End...
Endometrial Mix...
Endometrial Ser...
Endometrial Und...
Recurrent Endom...
Recurrent Endom...
Recurrent Endom...
Recurrent Endom...
Recurrent Endom...
Recurrent Endom...
Recurrent Endom...
Recurrent Endom...
Stage III Uteri...
Stage IV Uterin...
Carboplatin
Computed Tomogr...
Paclitaxel
Pembrolizumab
Placebo Adminis...
Quality-of-Life...
Questionnaire A...
18 Years - National Cancer Institute (NCI)
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial CancerNCT01935973
Endometrial Ade...
Endometrial Cle...
Endometrial Mix...
Endometrial Ser...
Endometrial Und...
Recurrent Uteri...
Laboratory Biom...
Trametinib
Uprosertib
18 Years - National Cancer Institute (NCI)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneNCT03660826
Endometrial Ade...
Endometrial Mix...
Endometrial Ser...
Endometrial Und...
Endometrioid Ad...
Stage IV Uterin...
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Capivasertib
Cediranib
Cediranib Malea...
Computed Tomogr...
Durvalumab
Echocardiograph...
Multigated Acqu...
Olaparib
18 Years - National Cancer Institute (NCI)
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial CancerNCT01935934
Endometrial Ade...
Endometrial Cle...
Endometrial Mix...
Endometrial Ser...
Metastatic Endo...
Recurrent Uteri...
Stage IV Uterin...
Stage IVA Uteri...
Stage IVB Uteri...
Uterine Corpus ...
Cabozantinib S-...
Laboratory Biom...
Pharmacological...
18 Years - National Cancer Institute (NCI)
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial CancerNCT02728258
Endometrial End...
Endometrial Mix...
Endometrial Ser...
Endometrial Und...
Metastatic Endo...
Recurrent Uteri...
Copanlisib
Laboratory Biom...
18 Years - NRG Oncology
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaNCT05112601
Endometrial Ade...
Endometrial Cle...
Endometrial Ded...
Endometrial End...
Endometrial Mix...
Endometrial Muc...
Endometrial Und...
Endometrioid Ad...
Recurrent Endom...
Biospecimen Col...
Computed Tomogr...
Ipilimumab
Magnetic Resona...
Nivolumab
18 Years - National Cancer Institute (NCI)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneNCT03660826
Endometrial Ade...
Endometrial Mix...
Endometrial Ser...
Endometrial Und...
Endometrioid Ad...
Stage IV Uterin...
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Capivasertib
Cediranib
Cediranib Malea...
Computed Tomogr...
Durvalumab
Echocardiograph...
Multigated Acqu...
Olaparib
18 Years - National Cancer Institute (NCI)
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological CancersNCT02020707
Cervical Adenoc...
Cervical Adenos...
Cervical Adenos...
Cervical Carcin...
Cervical Squamo...
Clinical Stage ...
Endometrial Ade...
Endometrial Cle...
Endometrial End...
Endometrial Mix...
Endometrial Muc...
Endometrial Ser...
Endometrial Und...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Malignant Femal...
Malignant Ovari...
Malignant Ovari...
Malignant Ovari...
Malignant Ovari...
Malignant Perit...
Malignant Solid...
Ovarian Carcino...
Ovarian Clear C...
Ovarian Endomet...
Ovarian High Gr...
Ovarian Mucinou...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Platinum-Resist...
Platinum-Resist...
Platinum-Resist...
Platinum-Sensit...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Unresectable Me...
Uterine Corpus ...
Bevacizumab
Laboratory Biom...
Nab-paclitaxel
Pharmacological...
18 Years - Mayo Clinic
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: